These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 8723745)

  • 1. Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538).
    Kumar GN; Grabowski B; Lee R; Denissen JF
    Drug Metab Dispos; 1996 May; 24(5):615-7. PubMed ID: 8723745
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
    Grubb MF; Diamond S; Christ DD
    Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
    Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
    Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of rat cytochrome P-450 by an investigational HIV protease inhibitor.
    Nishime JA; Wang RW; Lin JH; Chiba M
    Drug Metab Dispos; 1999 Sep; 27(9):972-6. PubMed ID: 10460793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
    Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II-selective induction of hepatic drug-metabolizing enzymes by oltipraz -5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione-, 1,7-phenanthroline, and 2,2'-dipyridyl in rats is not accompanied by induction of intestinal enzymes.
    Vargas M; Lamb JG; Franklin MR
    Drug Metab Dispos; 1998 Feb; 26(2):91-7. PubMed ID: 9456293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol.
    Horn TL; Long L; Cwik MJ; Morrissey RL; Kapetanovic IM; McCormick DL
    Chem Biol Interact; 2005 Apr; 152(2-3):79-99. PubMed ID: 15840382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
    Lin JH; Chiba M; Chen IW; Nishime JA; Vastag KJ
    Drug Metab Dispos; 1996 Dec; 24(12):1298-306. PubMed ID: 8971134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
    Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
    Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent subacute exposure to arsenic through drinking water and malathion via diet in male rats: effects on hepatic drug-metabolizing enzymes.
    Naraharisetti SB; Aggarwal M; Sarkar SN; Malik JK
    Arch Toxicol; 2008 Aug; 82(8):543-51. PubMed ID: 18528686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
    Gaedicke S; Firat-Geier E; Constantiniu O; Lucchiari-Hartz M; Freudenberg M; Galanos C; Niedermann G
    Cancer Res; 2002 Dec; 62(23):6901-8. PubMed ID: 12460905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.
    Lum PY; He YD; Slatter JG; Waring JF; Zelinsky N; Cavet G; Dai X; Fong O; Gum R; Jin L; Adamson GE; Roberts CJ; Olsen DB; Hazuda DJ; Ulrich RG
    Genomics; 2007 Oct; 90(4):464-73. PubMed ID: 17719200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
    Kempf DJ; Marsh KC; Kumar G; Rodrigues AD; Denissen JF; McDonald E; Kukulka MJ; Hsu A; Granneman GR; Baroldi PA; Sun E; Pizzuti D; Plattner JJ; Norbeck DW; Leonard JM
    Antimicrob Agents Chemother; 1997 Mar; 41(3):654-60. PubMed ID: 9056009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation.
    Lin JH; Chen IW; Chiba M; Nishime JA; Deluna FA
    Drug Metab Dispos; 2000 Apr; 28(4):460-6. PubMed ID: 10725315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity.
    Carlile DJ; Hakooz N; Houston JB
    Drug Metab Dispos; 1999 Apr; 27(4):526-32. PubMed ID: 10101148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
    Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
    Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.